Loading...
•
Mar 31, 2024
Puma Biotechnology Q1 2024 Earnings Report
Reported a net loss and a decrease in product revenue compared to the same quarter last year, while initiating a Phase II clinical trial for alisertib.
Key Takeaways
Puma Biotechnology reported a net loss of $4.8 million for Q1 2024, compared to a net income of $1.4 million in Q1 2023. Product revenue decreased to $40.3 million from $46.8 million year-over-year. The company initiated a Phase II clinical trial of alisertib monotherapy for extensive stage small cell lung cancer.
Net product revenue for Q1 2024 was $40.3 million, down from $46.8 million in Q1 2023.
GAAP net loss was $4.8 million, or $0.10 per share, compared to a net income of $1.4 million, or $0.03 per share, in the prior year.
Non-GAAP adjusted net loss was $2.4 million, or $0.05 per share, compared to non-GAAP adjusted net income of $4.2 million, or $0.09 per share, in the prior year.
Net cash provided by operating activities was $11.3 million, compared to $2.6 million in the first quarter of 2023.
Revenue by Segment
Forward Guidance
Puma Biotechnology provides financial outlook for the second quarter and full year 2024.
Positive Outlook
- Net Product Revenue: $43 - $45 million (Q2 2024)
- Royalty Revenue: $2.5 - $3 million (Q2 2024)
- Net Product Revenue: $183 - $190 million (Full Year 2024)
- Royalty Revenue: $30 - $33 million (Full Year 2024)
- License Revenue: $1 - $2 million (Full Year 2024)
Challenges Ahead
- Net Income/(Loss): $(6) - $(9) million (Q2 2024)
- Gross to Net Adjustment: 22% - 23% (Q2 2024)
- Net Income/(Loss): $12 - $15 million (Full Year 2024)
- Gross to Net Adjustment: 21.5% - 22.5% (Full Year 2024)
- License Revenue: $0 million (Q2 2024)
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...